Effect of 5-HI on platelet aggregation. (A) Chemical structure of 5-HI (5-hydroxyindolin-2-one, MW. 149.15). (B) 5-HI’s effect on collagen-induced human platelet aggregation. (C) 5-HI’s effect on thrombin-induced human platelet aggregation. (D) 5-HI’s effect on U46619-induced human platelet aggregation. (E) 5-HI’s effect on cytotoxicity. (F) Half maximal inhibitory concentration (IC50) value of 5-HI in collagen-induced human platelet aggregation. Platelet aggregation and cytotoxicity were carried out as described in “Materials and Methods” section. The data are expressed as the mean ± standard deviation (n = 4). * p < 0.05, ** p < 0.01 versus each agonist-stimulated human platelets. NS—not significant. Effect of 5-HI on [Ca2 + ]i mobilization, Ca2+ influx, IP3RI and ERK phosphorylation, and serotonin and ATP release. (A) Effect of 5-HI’s effect on collagen-induced [Ca2+]i mobilization. (B) 5-HI’s effect on thapsigargin-induced Ca2+ influx. (C) 5-HI’s effect on collagen-induced IP3RI phosphorylation. (D) 5-HI’s effect on collagen-induced ERK phosphorylation. (E) 5-HI’s effect on serotonin release. (F) 5-HI’s effect on ATP release. All experiments were performed as described in “Materials and Methods” section. The data are expressed as the mean ± standard deviation (n = 4). * p < 0.05, ** p < 0.01 versus the collagen-stimulated human platelets. Effect of 5-HI on TXA2 production and cPLA2 and p38MAPK phosphorylation. (A) 5-HI’s effect on collagen-induced TXA2 generation. (B) 5-HI’s effect on collagen-induced cPLA2 phosphorylation. (C) 5-HI’s effect on collagen-induced p38MAPK phosphorylation. All experiments were performed as described in “Materials and Methods” section. The data are expressed as the mean ± standard deviation (n = 4). * p < 0.05, ** p < 0.01 versus the collagen-stimulated human platelets. Effect of 5-HI on fibronectin adhesion, fibrinogen binding to αIIb/β3, and PI3K/Akt/VASP phosphorylation. (A) 5-HI’s effect on collagen-induced fibronectin adhesion. (B) The flow cytometry histograms on fibrinogen binding. (a), intact platelets (base); (b), collagen (2.5 μg/mL); (c), collagen (2.5 μg/mL) + 5-HI (75 μM); (d), collagen (2.5 μg/mL) + 5-HI (100 μM); (e), collagen (2.5 μg/mL) + 5-HI (150 μM); (f), collagen (2.5 μg/mL) + 5-HI (200 μM). (C) 5-HI’s effect on collagen-induced fibrinogen binding (%). (D) 5-HI’s effect on collagen-induced PI3K (Tyr458) phosphorylation. (E) 5-HI’s effect on collagen-induced Akt (Ser473) phosphorylation. (F) 5-HI’s effect on collagen-induced VASP (Ser157) phosphorylation. All experiments were performed as described in “Materials and Methods” section. The data are expressed as the mean ± standard deviation (n = 4). * p < 0.05, ** p < 0.01 versus the collagen-stimulated human platelets. Effect of 5-HI on cAMP concentration and fibrin clot retraction. (A) 5-HI’s effect on collagen-induced cAMP production. (B) Photographs of fibrin clot. (C) 5-HI’s effect on thrombin-retracted fibrin clot (%). All experiments were performed as describe in “Materials and Methods” section. The data are expressed as the mean ± standard deviation (n = 4). * p < 0.05 versus the unstimulated human PRP, † p < 0.05 versus the thrombin-stimulated human PRP. A schematic summary of inhibitory effects of 5-HI on platelet intracellular signaling pathway.